BCN, 19 Nov 2018: "Lysosomal disorders, a focus on Fabry Disease" Vall d'Hebron Seminar
- News 23 October 2018 1557 hits
On Monday, 19 November 2018, the Vall d'Hebron hosts the seminar entitled "Lysosomal disorders, a focus on Fabry Disease", from 8:30 am to 6 pm. The NANOMOL group co-organizes the event, through the CIBER-BBN and the project Smart-4-Fabry, coordinated by Dr. Nora Ventosa. This seminar is organized within the framework of the project Smart-4-Fabry.
Genetic deficiencies of lysosomal components, most commonly enzymes, are known as "lysosomal storage disorders" (LSDs) and lead to lysosomal dysfunction, broadly affecting peripheral organs and the central nervous system, debilitating patients and frequently causing fatality. This seminar will update clinicians and researchers on most recent advances in diagnosis, pathophysiology and management of Fabry disease as well as in emerging therapies in the treatment of LSD.
Day: Monday, November 19, 2018
Time: from 8:30 am to 6 pm
Venue: Sala d'Actes de Pavelló Docent, Vall d'Hebron HUVH
8:30: Opening session: Vall d’Hebron Hospital CEO & Director of Research Institute VHIR
9:00: Clinical management of Fabry disease. Chair: M. del Toro & G. Pintos-Morell
Miguel A. Torralba (Hospital Clínico, Zaragoza): Pathophysiology of Fabry disease: the role of biomarkers and genetic variants
Alberto Ortiz (Fundación Jiménez Díaz, Madrid): Overview of consensus treatment and precision medicine approach in Fabry disease
José Rodríguez Palomares (Hospital Universitari Vall d’Hebron, Barcelona): Insights into cardiovascular involvement in Fabry disease
Michael West (Dalhousie University, Halifax, Canada): What have we learned after 10 years of Canadian Fabry Disease Initiative (CFDI)
11.00: Coffee Break
11.30: New therapeutic strategies for lysosomal disorders. Chair: N. Ventosa & S. Schwartz Jr.
Ibane Abasolo (CIBBIM-Nanomedicine): Nanomedicine in lysosomal disorders. Project Smart4Fabry
Roberto Giugliani (Porto Alegre, Brazil): Fusion proteins and other strategies to cross the Blood-Brain-Barrier (BBB)
Michael West. (Dalhousie University, Halifax, Canada). Gene therapy clinical trial for Fabry disease
Fàtima Bosch. (CBATEG-UAB): Gene therapy approaches for Sanfilippo A and other lysosomal disorders
13:30: General Discussion
15.00: Current state of the treatment of lysosomal disorders.Chair: J. Torrent-Farnell
Personal experiences. Patients, relatives and healthcare staff.
18.00: Final summary, key messages to remember and farewell. Guillem Pintos-Morel
More informationTo register, please follow this link.
- Contact: email@example.com
- Download the flyer here
- Vall d'Hebron seminars
- Smart4Fabry project website
- NANOMOL website
- CIBER-BBN website
Related Topics: Meetings Participation